# A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects

> **NCT01262885** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 84 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** GSK2251052
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01262885
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-07
- **Primary completion:** 2011-08-25
- **Final completion:** 2011-08-25
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262885, "A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01262885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*